Pulse Biosciences Inc (PLSE) - Net Assets
Based on the latest financial reports, Pulse Biosciences Inc (PLSE) has net assets worth $66.30 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($81.62 Million) and total liabilities ($15.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Pulse Biosciences Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $66.30 Million |
| % of Total Assets | 81.23% |
| Annual Growth Rate | 15.79% |
| 5-Year Change | 125.99% |
| 10-Year Change | 218.82% |
| Growth Volatility | 75.09 |
Pulse Biosciences Inc - Net Assets Trend (2014–2025)
This chart illustrates how Pulse Biosciences Inc's net assets have evolved over time, based on quarterly financial data. See PLSE defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Pulse Biosciences Inc (2014–2025)
The table below shows the annual net assets of Pulse Biosciences Inc from 2014 to 2025. For live valuation and market cap data, see Pulse Biosciences Inc (PLSE) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $80.66 Million | -29.78% |
| 2024-12-31 | $114.86 Million | +158.93% |
| 2023-12-31 | $44.36 Million | +2073.31% |
| 2022-12-31 | $-2.25 Million | -106.30% |
| 2021-12-31 | $35.69 Million | +55.89% |
| 2020-12-31 | $22.89 Million | -25.52% |
| 2019-12-31 | $30.74 Million | -53.66% |
| 2018-12-31 | $66.33 Million | +44.22% |
| 2017-12-31 | $45.99 Million | +81.81% |
| 2016-12-31 | $25.30 Million | +85.13% |
| 2015-12-31 | $13.67 Million | -14.99% |
| 2014-12-31 | $16.07 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pulse Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46300444000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $68.00K | 0.08% |
| Other Components | $543.87 Million | 674.31% |
| Total Equity | $80.66 Million | 100.00% |
Pulse Biosciences Inc Competitors by Market Cap
The table below lists competitors of Pulse Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Westamerica Bancorporation
NASDAQ:WABC
|
$1.30 Billion |
|
Laurentian Bank Of Canada
TO:LB
|
$1.30 Billion |
|
Sunonwealth Electric Machine Industry Co Ltd
TW:2421
|
$1.30 Billion |
|
Fugro N.V.
AS:FUR
|
$1.30 Billion |
|
Ardent Health Partners, Inc.
NYSE:ARDT
|
$1.30 Billion |
|
Ipsos SA
PA:IPS
|
$1.30 Billion |
|
Superior Plus Corp
TO:SPB
|
$1.30 Billion |
|
Loma Negra Compania Industrial Argentina SA ADR
NYSE:LOMA
|
$1.30 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pulse Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 114,862,000 to 80,656,000, a change of -34,206,000 (-29.8%).
- Net loss of 72,781,000 reduced equity.
- Share repurchases of 586,000 reduced equity.
- Other factors increased equity by 39,161,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-72.78 Million | -90.24% |
| Share Repurchases | $586.00K | -0.73% |
| Other Changes | $39.16 Million | +48.55% |
| Total Change | $- | -29.78% |
Book Value vs Market Value Analysis
This analysis compares Pulse Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 21.27x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.98x to 21.27x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $6.40 | $25.45 | x |
| 2015-12-31 | $1.81 | $25.45 | x |
| 2016-12-31 | $2.30 | $25.45 | x |
| 2017-12-31 | $3.12 | $25.45 | x |
| 2018-12-31 | $3.88 | $25.45 | x |
| 2019-12-31 | $1.48 | $25.45 | x |
| 2020-12-31 | $0.98 | $25.45 | x |
| 2021-12-31 | $1.28 | $25.45 | x |
| 2022-12-31 | $-0.07 | $25.45 | x |
| 2023-12-31 | $0.92 | $25.45 | x |
| 2024-12-31 | $1.97 | $25.45 | x |
| 2025-12-31 | $1.20 | $25.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pulse Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -90.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -20794.57%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.19x
- Recent ROE (-90.24%) is below the historical average (-79.10%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -2.95% | 0.00% | 0.00x | 1.11x | $-2.08 Million |
| 2015 | -20.57% | 0.00% | 0.00x | 1.05x | $-4.18 Million |
| 2016 | -37.62% | -13997.06% | 0.00x | 1.04x | $-12.05 Million |
| 2017 | -55.59% | -10351.01% | 0.00x | 1.08x | $-30.17 Million |
| 2018 | -56.60% | 0.00% | 0.00x | 1.06x | $-44.18 Million |
| 2019 | -149.62% | 0.00% | 0.00x | 1.36x | $-49.06 Million |
| 2020 | -217.25% | -43628.95% | 0.00x | 1.80x | $-52.03 Million |
| 2021 | -176.97% | -4454.16% | 0.03x | 1.52x | $-66.73 Million |
| 2022 | 0.00% | -8421.86% | 0.01x | 0.00x | $-58.73 Million |
| 2023 | -95.15% | 0.00% | 0.00x | 1.33x | $-46.65 Million |
| 2024 | -46.65% | 0.00% | 0.00x | 1.15x | $-65.07 Million |
| 2025 | -90.24% | -20794.57% | 0.00x | 1.19x | $-80.85 Million |
Industry Comparison
This section compares Pulse Biosciences Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,252,702,307
- Average return on equity (ROE) among peers: -94.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pulse Biosciences Inc (PLSE) | $66.30 Million | -2.95% | 0.23x | $1.30 Billion |
| Akoya Biosciences Inc (AKYA) | $7.59 Million | -728.97% | 15.46x | $64.44 Million |
| Align Technology Inc (ALGN) | $-84.67 Million | 0.00% | 0.00x | $12.09 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $447.90 Million |
| AptarGroup Inc (ATR) | $2.71 Billion | 14.48% | 0.94x | $7.66 Billion |
| AtriCure Inc (ATRC) | $483.76 Million | 10.38% | 0.27x | $1.37 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.52 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $18.90 Million | -243.53% | 0.62x | $924.75 Million |
| Avantor Inc (AVTR) | $4.86 Billion | 14.14% | 1.77x | $5.44 Billion |
| Azenta Inc (AZTA) | $121.80 Million | -15.11% | 0.16x | $1.05 Billion |
| Baxter International Inc (BAX) | $4.09 Billion | 0.98% | 1.08x | $9.94 Billion |
About Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac… Read more